Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1966 4
1967 2
1968 5
1969 19
1970 10
1971 6
1972 10
1973 11
1974 22
1975 8
1976 9
1977 12
1978 17
1979 15
1980 16
1981 14
1982 17
1983 28
1984 24
1985 34
1986 15
1987 19
1988 25
1989 20
1990 25
1991 33
1992 11
1993 13
1994 12
1995 24
1996 19
1997 19
1998 18
1999 24
2000 32
2001 23
2002 27
2003 29
2004 28
2005 26
2006 27
2007 28
2008 32
2009 49
2010 46
2011 40
2012 45
2013 42
2014 39
2015 34
2016 33
2017 49
2018 45
2019 48
2020 58
2021 51
2022 50
2023 51
2024 22

Text availability

Article attribute

Article type

Publication date

Search Results

1,407 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Malignant adrenal gland pheochromocytoma"
Page 1
Pheochromocytoma, diagnosis and treatment: Review of the literature.
Farrugia FA, Martikos G, Tzanetis P, Charalampopoulos A, Misiakos E, Zavras N, Sotiropoulos D. Farrugia FA, et al. Endocr Regul. 2017 Jul 1;51(3):168-181. doi: 10.1515/enr-2017-0018. Endocr Regul. 2017. PMID: 28858847 Free article. Review.
OBJECTIVE: We conducted an extensive review of the literature and tried to cite the most recent recommendations concerning the pheochromocytoma (PHEO). METHODS: Pub Med and Google Scholar databases were searched systematically for studies concerning pheochromocytomas …
OBJECTIVE: We conducted an extensive review of the literature and tried to cite the most recent recommendations concerning the pheochromo …
Targeted Therapies in Pheochromocytoma and Paraganglioma.
Wang K, Crona J, Beuschlein F, Grossman AB, Pacak K, Nölting S. Wang K, et al. J Clin Endocrinol Metab. 2022 Nov 23;107(11):2963-2972. doi: 10.1210/clinem/dgac471. J Clin Endocrinol Metab. 2022. PMID: 35973976 Free PMC article. Review.
Some tyrosine kinase inhibitors (sunitinib, cabozantinib) are already in clinical use with some promising results, but without formal approval for the treatment of PPGLs. Sunitinib is the only therapeutic option which has been investigated in a randomized placebo-co …
Some tyrosine kinase inhibitors (sunitinib, cabozantinib) are already in clinical use with some promising results, but without formal …
Endocrine Fever.
Kalra S, Bhattacharya S, Dhingra A, Khare J, Jindal S. Kalra S, et al. J Pak Med Assoc. 2024 May;74(5):998-999. doi: 10.47391/JPMA.24-36. J Pak Med Assoc. 2024. PMID: 38783456 Free article. Review.
Additionally, several endocrine disorders, including hyperthyroidism, subacute thyroiditis, carcinoid syndrome, and pheochromocytoma, can manifest as fever. Furthermore, fever can be an adverse effect of various endocrine treatments, such as bisphosphonates and antithyroid …
Additionally, several endocrine disorders, including hyperthyroidism, subacute thyroiditis, carcinoid syndrome, and pheochromocytoma, …
Malignant pheochromocytoma and paraganglioma: management options.
Corssmit EPM, Snel M, Kapiteijn E. Corssmit EPM, et al. Curr Opin Oncol. 2020 Jan;32(1):20-26. doi: 10.1097/CCO.0000000000000589. Curr Opin Oncol. 2020. PMID: 31599769 Review.
PURPOSE OF REVIEW: Although the majority of pheochromocytoma and paraganglioma are benign, 15-17% develop metastatic disease, being present at the initial diagnosis in about 11-31% of cases. ...For individual patients, overall survival, progression-free survival, and cl …
PURPOSE OF REVIEW: Although the majority of pheochromocytoma and paraganglioma are benign, 15-17% develop metastatic disease, being p …
Adrenal autotransplantation.
Srougi M, Gittes RF. Srougi M, et al. Urol Surv. 1978 Apr;28(2):41-8. Urol Surv. 1978. PMID: 209598 Review.
The aim of this review is to bring to mind the possibility of autografting adrenal glands in some clinical situations and to emphasize some points that could be relevant in obtaining successful results. The available data justify clinical trials with t …
The aim of this review is to bring to mind the possibility of autografting adrenal glands in some clinical situations a …
Pheochromocytoma and glucoregulation disorders.
Derrou S, Bouziane T, Salhi H, El Ouahabi H. Derrou S, et al. Ann Afr Med. 2021 Jan-Mar;20(1):42-45. doi: 10.4103/aam.aam_13_20. Ann Afr Med. 2021. PMID: 33727511 Free PMC article.
INTRODUCTION: Pheochromocytomas are catecholamine-producing tumors presenting with various clinical symptoms and a serious potentially lethal cardiovascular complications due to the potent effects of secreted catecholamines. ...RESULTS: Overall, 23 patients underwen …
INTRODUCTION: Pheochromocytomas are catecholamine-producing tumors presenting with various clinical symptoms and a serious pot …
Pheochromocytoma.
Bravo EL. Bravo EL. Cardiol Rev. 2002 Jan-Feb;10(1):44-50. doi: 10.1097/00045415-200201000-00009. Cardiol Rev. 2002. PMID: 11790269 Review.
Pheochromocytomas cause the most dramatic, life-threatening crises in all of endocrinology. Pheochromocytoma is an explosive clinical syndrome characterized by severe hypertension associated with cardiac complications, hypotension, or even shock and sudden de …
Pheochromocytomas cause the most dramatic, life-threatening crises in all of endocrinology. Pheochromocytoma is an explosive …
Catecholamine-induced hypertensive crises: current insights and management.
Nazari MA, Hasan R, Haigney M, Maghsoudi A, Lenders JWM, Carey RM, Pacak K. Nazari MA, et al. Lancet Diabetes Endocrinol. 2023 Dec;11(12):942-954. doi: 10.1016/S2213-8587(23)00256-5. Epub 2023 Nov 6. Lancet Diabetes Endocrinol. 2023. PMID: 37944546 Review.
Phaeochromocytomas and paragangliomas (PPGLs) release catecholamines leading to catecholamine-induced hypertensive (CIH) crises, with blood pressure greater than or equal to 180/120 mm Hg. ...Here, we combine relevant evidence, 60 years of collective clinical experi …
Phaeochromocytomas and paragangliomas (PPGLs) release catecholamines leading to catecholamine-induced hypertensive (CIH) crises, with …
SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma.
Perez K, Jacene H, Hornick JL, Ma C, Vaz N, Brais LK, Alexander H, Baddoo W, Astone K, Esplin ED, Garcia J, Halperin DM, Kulke MH, Chan JA. Perez K, et al. Endocr Relat Cancer. 2022 Jul 19;29(9):533-544. doi: 10.1530/ERC-21-0392. Print 2022 Sep 1. Endocr Relat Cancer. 2022. PMID: 35731023
Malignant pheochromocytomas (PHEOs)/paragangliomas (PGLs) are rare tumors for which clinical outcomes remain poorly defined and therapeutic options are limited. ...Our series represents one of the largest analyses of patients with malignant PHEOs/PGLs …
Malignant pheochromocytomas (PHEOs)/paragangliomas (PGLs) are rare tumors for which clinical outcomes remain poorly def …
I-131 Metaiodobenzylguanidine Therapy of Pheochromocytoma and Paraganglioma.
Carrasquillo JA, Pandit-Taskar N, Chen CC. Carrasquillo JA, et al. Semin Nucl Med. 2016 May;46(3):203-14. doi: 10.1053/j.semnuclmed.2016.01.011. Semin Nucl Med. 2016. PMID: 27067501 Review.
Pheochromocytomas and paragangliomas are rare tumors arising from chromaffin cells. ...I-131 MIBG is taken up via specific receptors and localizes into many but not all pheochromocytomas and paragangliomas. Because these tumors are rare, most therapy studies are ret …
Pheochromocytomas and paragangliomas are rare tumors arising from chromaffin cells. ...I-131 MIBG is taken up via specific receptors …
1,407 results